GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses

Phase 1

Completed

Conditions: Infections, Respiratory Tract

First Posted Date: 2012-06-11

Last Posted Date: 2017-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 86

Registration Number: NCT01615796

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Other: Subjects with COPD
Other: Subjects without COPD

First Posted Date: 2012-06-11

Last Posted Date: 2012-06-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40884

Registration Number: NCT01615783

Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

Phase 2

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Synflorix™
Biological: Prevnar 13™
Biological: Pneumococcal conjugate vaccine GSK2830929A
Biological: Pneumococcal conjugate vaccine GSK2830930A
Biological: Infanrix hexa™

First Posted Date: 2012-06-11

Last Posted Date: 2019-07-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 953

Registration Number: NCT01616459

Locations: 🇪🇸
GSK Investigational Site, Valladolid, Spain

Japanese Phase I of GSK1605786

Phase 1

Completed

Conditions: Crohn's Disease

Interventions: Drug: GSK1605786
Drug: GSK1605786 Placebo

First Posted Date: 2012-06-05

Last Posted Date: 2017-06-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT01611805

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Phase 1

Completed

Conditions: Infections, Bacterial

Interventions: Drug: 500mg IV GSK1322322/placebo
Drug: 1000mg oral GSK1322322/placebo
Drug: 1500mg oral GSK1322322/placebo dose
Drug: 2000mg IV GSK1322322J/placebo
Drug: 3000mg IV GSK1322322J/placebo
Drug: 1000mg IV GSK1322322J/placebo
Drug: 1000mg IV GSK1322322/placebo
Drug: 1500mg IV GSK1322322/placebo